On June 17, 2025 Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing first-of-its-kind targeted therapies for primary and metastatic breast cancer, reported the peer-reviewed publication in PLOS-One of their dose optimization in-vivo study results of ZetaMast (Zeta-MBC-005) (Press release, Zetagen Therapeutics, JUN 17, 2025, View Source [SID1234653955]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zetagen identified two concentrations of ZetaMast (Zeta-MBC-005) which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin.
"Patients with disseminated metastatic breast cancer involving the liver, face a poor prognosis and new approaches are urgently needed., stated Debasish Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX "Although some therapies have been designed for direct administration for liver metastases, they have not demonstrated efficacy in significantly improving survival. ZetaMast is an innovative therapeutic approach that has demonstrated systemic biological effects potentially extending beyond liver metastases in preclinical models, offering promising potential to enhance outcomes in this setting."
ZetaMast (Zeta-MBC-005) Increased Survival in a Mouse Xenograft Liver Metastases Model. The 4T1, TNBC cell line, tagged with luc2 luciferase (4T1-luc2), was implanted directly into the liver of BALB/c mice. Seven days after tumor inoculation, mice were treated with various concentrations via a single administration of ZetaMast (Zeta-MBC-005) (30-, 60-, 120-, 180-, 240-, or 480-μg) in combination with 5-mg/kg doxorubicin. Mice in the Control group received 5 mg/kg of doxorubicin and the ZetaMast (Zeta-MBC-005) carrier without Zetagen’s small molecule, administered every72-hours.
ZetaMast (Zeta-MBC-005) has the ability to deliver Zetagen’s small molecules intratumorally as well as other therapies, avoiding off-target side effects.
"Effective locoregional therapies are likely the key to reducing breast cancer mortality for patients with disseminated metastatic disease and increasing 5-year survival above 31%. If treatments like ZetaMast (Zeta-MBC-005) can be given when and where needed, increasing the duration of overall tumor control, which may be enough to tip the balance towards a favorable impact on survival.," stated Bryan S. Margulies, MS, Ph.D., CSO of Zetagen.
To view the ZetaMAST (Zeta-MBC-005) dose optimization study results go to View Source
About ZetaMAST (Zeta-MBC-005)
ZetaMast (Zeta-MBC-005) is a proprietary drug eluting carrier designed for locoregional administration, controlled release of two small molecules in the treatment of multifocal, unresectable, liver metastases from breast cancer with the potential to increase survival rates.
The USPTO has granted Zetagen a "Composition of Matter" patent for ZetaMast (Zeta-MBC-005), and Zetagen has also submitted a filing to the FDA for Orphan Drug Designation.
Zetagen is finalizing preparations for an FDA IND submission this fall, with a Phase Ib clinical trial set to commence early 2026.